WASHINGTON (Reuters) - A U.S. Food and Drug Administration panel of outside experts on Thursday recommended Sanofi SA's and Isis Pharmaceutical Inc's drug, Kynamro, for treatment of a rare genetic disorder that causes unusually high cholesterol and life-threatening cardiovascular disease.
(Reporting by David Morgan; Editing by Gerald E. McCormick)
